Wealthfront Advisers LLC Sells 6,410 Shares of Amgen Inc. $AMGN

Key Points

• Wealthfront Advisers cut its Amgen stake by 7.1%, selling 6,410 shares and retaining 84,152 shares valued at approximately $30.5 million. Institutional investors collectively own 76.5% of the company.
• Amgen reported quarterly EPS of $6.29 and revenue of $10.05 billion, beating consensus estimates by $0.67 and $620 million, respectively; revenue increased 9.5% year over year. The company also declared a quarterly dividend of $2.52 per share, representing a 2.3% annual yield.
• Shares recently traded near their 52-week high after rising 4%, but analyst sentiment remains mixed: MarketBeat lists an average rating of “Hold” with a $379.36 price target, below the reported trading price.

Wealthfront Advisers LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,152 shares of the medical research company's stock after selling 6,410 shares during the quarter. Wealthfront Advisers LLC's holdings in Amgen were worth $30,473,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Adell Harriman & Carpenter Inc. grew its position in Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company's stock worth $7,204,000 after acquiring an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Amgen in the 4th quarter valued at $22,441,000. Sigma Planning Corp boosted its stake in Amgen by 24.0% in the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company's stock worth $5,889,000 after purchasing an additional 3,488 shares in the last quarter. National Pension Service boosted its stake in Amgen by 4.7% in the fourth quarter. National Pension Service now owns 1,239,549 shares of the medical research company's stock worth $405,717,000 after purchasing an additional 55,489 shares in the last quarter. Finally, Integrated Advisors Network LLC grew its holdings in shares of Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock worth $6,664,000 after purchasing an additional 6,356 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen was highlighted as one of the best-performing U.S. large-cap drugmakers in 2026, outperforming peers Merck and Pfizer despite lacking an obesity drug. The comparison reinforces investor confidence in Amgen’s existing portfolio and operating execution. Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
• Positive Sentiment: Healthcare-sector strength and a rotation toward profitable drugmakers helped lift Amgen, while renewed enthusiasm for biotechnology also improved sentiment across the industry. Amgen Stock Surges as Healthcare Hits Record High
• Positive Sentiment: Argus raised its Amgen price target from $375 to $460 and maintained a “buy” rating, citing additional upside for the shares. Argus price-target update
• Neutral Sentiment: Amgen’s latest quarterly results beat consensus estimates for earnings and revenue, with revenue growth accelerating year over year. Full-year earnings guidance and expectations for continued growth remain important supports for the investment case.
• Neutral Sentiment: The obesity-drug market is becoming more selective, and Amgen is reportedly trimming some early-stage efforts. This could improve capital discipline, but it also highlights execution risk as the company competes in a crowded field. Obesity investing’s way forward, mapped
• Negative Sentiment: Although Cantor Fitzgerald and Mizuho raised their price targets, both retained “neutral” ratings and set targets below the current trading level, signaling valuation concerns after Amgen’s strong run. Analyst price-target updates

Amgen Trading Up 4.0%

AMGN stock opened at $442.36 on Thursday. The company has a market cap of $239.15 billion, a P/E ratio of 27.49, a PEG ratio of 3.95 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $443.20. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The business has a fifty day moving average of $375.75 and a 200-day moving average of $360.76.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm's quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts expect that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen's dividend payout ratio is presently 62.65%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on AMGN shares. Piper Sandler restated an "overweight" rating on shares of Amgen in a research note on Friday, June 12th. TD Cowen upped their price target on shares of Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Cantor Fitzgerald increased their price objective on shares of Amgen from $350.00 to $400.00 and gave the stock a "neutral" rating in a report on Tuesday. Sanford C. Bernstein raised their price objective on shares of Amgen from $335.00 to $345.00 and gave the company a "market perform" rating in a research report on Thursday, August 6th. Finally, Wells Fargo & Company boosted their target price on shares of Amgen from $390.00 to $400.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $379.36.

Insider Activity

In other news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 in the last ninety days. Insiders own 0.85% of the company's stock.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source